The introduction of monoclonal antibodies (mAbs) in the 1980 s enabled the selective targeting of tumor-associated antigens, exemplified by trastuzumab (targeting HER2) and rituximab (targeting CD20). This evidence concerns the gene ERBB2 and neoplasm.